SAN DIEGO, April 28, 2015 /PRNewswire/ -- Human Longevity, Inc. (HLI), the genomic-driven health information technology company, today announced that the company has received certification under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). Under the "deemed status" provision of the U.S. Department of Health and Human Services' (HHS) Center for Medicare and Medicaid Services (CMS), the state of California has granted the company's initial CLIA clinical laboratory license.
"Thanks to the hard work of our laboratory team, including Arthur Baca, M.D. Ph.D. and William Biggs, Ph.D., we have completed this important regulatory milestone for HLI," said J. Craig Venter, Ph.D., HLI CEO and Co-Founder. Dr. Baca serves as HLI's CLIA Laboratory Director and has held leadership roles at several CLIA-Certified/CAP-Accredited clinical laboratories. As Head of HLI's Genomic Sequencing, Dr. Biggs oversees the largest human genomic sequencing facility in the world.
HLI has set out to integrate whole genome sequence data with extensive and unique clinical measures and imaging within the HLI Knowledgebase™. The combined high quality, comprehensive data will continue to enrich the HLI Knowledgebase™, which includes the company's proprietary informatics analysis and data interpretation and integration. The Knowledgebase™ forms the core of HLI's business. The company is pursuing agreements with a variety of customers including pharmaceutical and biotech companies, academic health systems, governments and insurers.
The CLIA regulations include federal standards applicable to all U.S. facilities or sites that test human specimens for health assessment or to diagnose, prevent, or treat disease. CMS regulates this testing in the United States through the CLIA. The Centers for Disease Control and Prevention (CDC), in partnership with CMS and FDA, supports the CLIA program and clinical laboratory quality.
About Human Longevity, Inc.
HLI, a privately held company headquartered in San Diego, CA was founded in 2013 by pioneers in the fields of genomics and stem cell therapy. Using advances in genomic sequencing, the human microbiome, proteomics, informatics, computing, and cell therapy technologies, HLI is building the world's most comprehensive database of human genotypes and phenotypes as a basis for a variety of commercialization opportunities to help solve aging related disease and human biological decline. HLI will be licensing access to its database, and developing new diagnostics and therapeutics as part of their product offerings. For more information please visit www.humanlongevity.com.
SOURCE Human Longevity, Inc.